Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:13:17.548Z.
Calculation as of: 2026-10-06T19:13:17.548Z.
Quote observation: 2026-10-06T19:06:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8a2308f447f4e5493ab7c030002cc6e6bdf496bcf8061e6c96b03dd90007620
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precipio, Inc. (PRPO) | $41.95M | N/A | N/A | N/A | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.59M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $43.14M | N/A | 7.83 | 14.59 | 14.59 |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.99M | N/A | N/A | N/A | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.60M | N/A | N/A | N/A | N/A |
| CVRx, Inc. (CVRX)vs › | $43.52M | N/A | N/A | N/A | N/A |
| Veru Inc. (VERU)vs › | $39.80M | N/A | 243.89 | 230.07 | 202.94 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $39.15M | N/A | N/A | N/A | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $45.10M | 5.80 | 15.10 | 15.10 | 15.10 |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.77M | N/A | 328.93 | 271.56 | 151.89 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$23.52
Forward EPS (Est.)
$27.40
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
